At the American Society of Human Genetics (ASHG) Annual Meeting (Nov. 5-9, 2024), Complete Genomics, a pioneering genomic sequencing company, will highlight an expanded application menu and broader market adoption of its flagship sequencer DNBSEQ-T7 ™ and a series of product launches and new innovations.

Over the last year, Complete Genomics' flagship sequencer, DNBSEQ-T7 has gained more adoption in the market for its flexibility, catering to the industry trend of sequencing more modalities (multi-omics from DNA/RNA to protein), at a lower cost and higher resolution (from bulk to single cell and spatial omics), through an expanded menu of applications to enable human genetics research using DNBSEQ CompleteWGS, spatial transcriptomics, proteomics, and single cell sequencing.

"Aligning with the industry's demand to rapidly provide more data at a lower cost point, in 2024, our flagship high throughput sequencer, DNBSEQ-T7, gained good traction in the high throughput sequencing market," said Rob Tarbox, VP of Product and Marketing at Complete Genomics.